Skip to content
Evigrade
CriticalDirect oral anticoagulants (factor Xa inhibitors)×Vitamin K antagonist anticoagulants

Updated · Methodology

Mechanism

Edoxaban directly and reversibly inhibits clotting factor Xa and so reduces thrombin generation (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Warfarin prevents the liver from forming active clotting factors II, VII, IX and X by inhibiting the vitamin K-mediated gamma-carboxylation of their precursor proteins (warfarin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is contraindicated with any other anticoagulant because of the increased risk of bleeding, and this contraindication names warfarin (EMA). Edoxaban itself prolongs the prothrombin time and the international normalised ratio (INR). With a vitamin K antagonist, it can raise the INR after an edoxaban dose by up to 46% (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site (EMA). With warfarin, too, the most serious risk is bleeding in any tissue or organ (warfarin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

Edoxaban is contraindicated with any other anticoagulant, including warfarin, except when switching from one oral anticoagulant to another (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, FDA). When switching from warfarin to edoxaban, stop warfarin and start edoxaban once the international normalised ratio (INR) is 2.5 or lower (EMA). When switching from edoxaban to warfarin, keep anticoagulation continuous. With the oral option, patients on 60 mg take edoxaban 30 mg once daily together with a suitable warfarin dose. Patients on 30 mg (creatinine clearance 15–50 mL/min, body weight 60 kg or less, or certain P-glycoprotein inhibitors) take 15 mg once daily. Do not give a warfarin loading dose (EMA). During the first 14 days of co-administration, the edoxaban SmPC recommends measuring the INR at least three times, just before the daily edoxaban dose. Stop edoxaban once the INR reaches 2.0. After 14 days, the SmPC recommends stopping edoxaban and continuing to adjust the warfarin dose to an INR of 2–3 (EMA). With the parenteral option, stop edoxaban and start a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose. Stop the parenteral anticoagulant once the INR is stable at 2.0 or higher (EMA). Measure the INR more often whenever other medicines are started, stopped or taken irregularly. Monitor coagulation closely when any drug is added to or withdrawn from a coumarin anticoagulant (warfarin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If severe bleeding occurs, stop edoxaban. There is no specific antidote, and vitamin K is not expected to affect edoxaban activity (EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Edoxaban

Other interactions with Warfarin